2. Immunology/Inflammation Apoptosis
  3. CD28 Apoptosis
  4. Galiximab

Galiximab  (Synonyms: 加利昔单抗; IDEC 114; Anti-Human CD80 Recombinant Antibody)

目录号: HY-P99293 纯度: 99.23%
COA 技术支持

Galiximab (IDEC 114) 是一种靶向 CD80 的灵长类化单克隆 IgG1 抗体。Galiximab 的可变区是灵长类源化，恒定区是人源化。Galiximab 通过阻断 CD80-CD28 结合，诱导抗体依赖细胞毒性。Galiximab 具有抗肿瘤的活性，能够诱导肿瘤细胞凋亡 (apoptosis)。Galiximab 可用于复发性霍奇金淋巴瘤和实体瘤的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 357613-77-5

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥3000
In-stock
5 mg ￥9500
In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Galiximab 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors[1][2].

同型

Human IgG1 lambda1
推荐同型对照抗体
种属

Humanized
IC50 & Target

CD28L/CD80
体外研究
(In Vitro)

Galiximab (25-100 μg/mL; 36 h) 在 Raji 细胞中与 Doxorubicin (HY-15142A) 联用显著增强细胞凋亡[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Galiximab 相关抗体:

Apoptosis Analysis[1]

Cell Line: Raji cells treated Doxorubicin (HY-15142A) (0.05-1 µg/mL)
Concentration: 25, 50 and 100 μg/mL
Incubation Time: 36 h
Result: Enhanced cell apoptosis in a dose-dependent manner.
体内研究
(In Vivo)

Galiximab (0.1-30 mg/kg; 腹腔注射; 每周 1 次; 共 3-4 次) 在小鼠 Raji 和 SKW6.4 肿瘤模型中具有抗肿瘤的活性[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CB17 SCID mice aged 6-8 weeks old treated Raji cells or SKW6.4 cells[1]
Dosage: Raji model: 0.1, 1, 3, 10, 30 mg/kg; once weekly; 3 times in total
SKW6.4 model: 5, 10, 30 mg/kg; once weekly; 4 times in total
Administration: Intraperitoneal injection
Result: Showed dose-dependent tumor growth inhibition and survival prolongation in both models.
Clinical Trial
基因 ID

941  [NCBI]

Accession
应用

ELISA, FACS, Functional assay
偶联物

Unconjugated
复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.
分子量

145.24 kDa

CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

加利昔单抗
运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 lambda
纯度 & 产品资料

纯度: 99.23%

COA (265 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Galiximab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Galiximab357613-77-5IDEC 114 Anti-Human CD80 Recombinant Antibody加利昔单抗IDEC114IDEC-114CD28ApoptosisB-cell lymphomamonoclonal antibody Raji cellsSKW6.4 cellsInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Galiximab
目录号：
HY-P99293
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z